AKAO Achaogen Inc.

13.48
-0.09  -1%
Previous Close 13.57
Open 13.60
Price To book 3.19
Market Cap 569304951
Shares 42,233,305
Volume 518,242
Short Ratio 12.11
Av. Daily Volume 685,958

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated 1H 2018.
C-Scape
Complicated urinary tract infections (cUTI) due to multi-drug resistant (MDR) pathogens
Phase 3 data released December 12, 2016 - primary endpoint met. NDA filing due 2H 2017.
Plazomicin - EPIC trial
Complicated urinary tract infections (cUTI)
Phase 3 data released December 12, 2016 - primary endpoint met. NDA filing due 2H 2017.
Plazomicin - CARE
Serious bacterial infections due to carbapenem-resistant Enterobacteriaceae (CRE)

Latest News

  1. Should You Have Achaogen Inc’s (AKAO) In Your Portfolio?
  2. Achaogen IDWeek 2017 Presentations Feature Plazomicin’s Unique Potential to Treat MDR Enterobacteriaceae
  3. ETFs with exposure to Achaogen, Inc. : October 3, 2017
  4. Achaogen Awarded up to $18 Million Contract by BARDA to Support Development of Orally-Administered Antibacterial Candidate C-Scape
  5. Achaogen Announces Multiple Plazomicin Presentations at IDWeek 2017
  6. Achaogen Announces New Employment Inducement Grants
  7. ETFs with exposure to Achaogen, Inc. : September 18, 2017
  8. Achaogen to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference
  9. Achaogen Adds Liz Bhatt as Chief Business Officer
  10. Achaogen, Inc. :AKAO-US: Earnings Analysis: Q2, 2017 By the Numbers : September 5, 2017
  11. Edited Transcript of AKAO earnings conference call or presentation 3-Aug-17 8:30pm GMT
  12. Achaogen to Present at the Wedbush PacGrow Healthcare Conference
  13. Achaogen reports 2Q loss
  14. Achaogen, Inc. – Value Analysis (NASDAQ:AKAO) : August 4, 2017
  15. Achaogen Reports Second Quarter 2017 Financial Results and Provides Corporate Update
  16. Investor Network: Achaogen, Inc. to Host Earnings Call
  17. ETFs with exposure to Achaogen, Inc. : July 27, 2017
  18. Achaogen to Host Conference Call and Webcast of Second Quarter 2017 Financial Results on August 3, 2017

SEC Filings

  1. CT ORDER - Confidential treatment order 171111610
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171014757
  3. 8-K - Current report 171004830
  4. 8-K/A [Amend] - Current report 17999898
  5. SC 13G - Statement of acquisition of beneficial ownership by individuals 17983439
  6. 8-K - Current report 17982862
  7. 8-K - Current report 17963959
  8. CT ORDER - Confidential treatment order 17935194
  9. 8-K - Current report 17913597
  10. 8-K - Current report 17881055